Becker's Healthcare December 7, 2023
After a nearly nine-month review, the Biden administration has determined it has the authority to seize the patents of certain high-priced drugs developed with taxpayer funds — a policy known as march-in rights.
People familiar with the matter told Politico in a Dec. 6 report that the administration will not endorse widespread use of the policy and isn’t planning to target any individual medicines. A day later, the White House released a framework recommending the factors federal agencies should consider when determining when to use march-in rights, which, for the first time, specifies that a medication’s price can be a factor in determining whether to break a patent and share it with other...
Today's Sponsors
Today's Sponsor